You are here

Imprimis to Offer Compounded Alternative to Restasis

Announcement follows judge’s ruling to toss patents

Days after a federal judge threw out patents on the dry-eye medicine Restasis (Allergan), a San Diego pharmaceutical company said it would offer a cheaper compounded version of cyclosporine. Shares of Imprimis Pharmaceuticals nearly doubled after the announcement.

Allergan last month sued Imprimis alleging the company is illegally manufacturing and selling unapproved new drugs. Imprimis called the lawsuit frivolous and a tactic to snuff out competition offering lower cost options to expensive drugs, Reuters reported.

The Imprimis product will cost 99 cents for a month’s supply and refills start at $79 a month.

Allergan recently stirred controversy after striking a deal with a Native American tribe that would shield certain patents on Restasis, which can cost $5,000 a year according to Imprimis. A U.S. judge Monday invalidated those patents on Restasis on the grounds that they cover ideas that are obvious.

Imprimis  said its compounded cyclosporine-based formulations are made from FDA-approved drug components and compounded in FDA-inspected facilities, require a patient-specific prescription, and may be customized according to patients' individual needs.

Topical cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when purchased in the commercially available form of Restasis, Imprimis said. 

Sources: Reuters; October 19, 2017; Imprimis; October 19, 2017.

More Headlines

Some see the loss of an important, unbiased source of information.
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
The move is considered part of the antiterrorism effort.
An impurity has been found to be carcinogenic.
But diabetes group tamp down expectations.
Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.